Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $23 price target.
May 08, 2024 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Inozyme Pharma with a $23 price target.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst like Joseph Stringer could lead to increased investor confidence in Inozyme Pharma, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100